ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS announced the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This significant milestone marks an important step towards enabling a clinical trial application. The Company is currently focusing on Good Manufacturing Practice (GMP) production and designing the Phase I clinical trial, with the aim to initiate the Phase I trial within the next year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.545 SEK | -2.12% | -8.45% | +20.62% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.62% | 11.91M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.54% | 31.28B | |
+57.86% | 25.27B | |
-15.27% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.53% | 7.94B |
- Stock Market
- Equities
- EXPRS2 Stock
- News ExpreS2ion Biotech Holding AB
- ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate